Novo Nordisk and telehealth firm Hims & Hers reached an agreement under which Novo will supply its GLP‑1 medicines through Hims at the same prices other telehealth providers offer, and Hims will stop promoting compounded knockoffs. Novo will dismiss a pending patent suit against Hims while reserving the right to refile later. The deal follows regulatory scrutiny of compounded GLP‑1 products and represents a commercial path to restore branded supply through a leading digital provider. Novo said the agreement expands patient access to FDA‑approved options; Hims agreed to transition existing patients to approved medicines and curtail promotion of unapproved compounded formulations.